Latest Investments News

Aura Energy has successfully raised A$20 million through a heavily oversubscribed placement, aiming to accelerate development at its Tiris Uranium Project amid rising global uranium demand.

Yowie Group has landed a three-year seasonal licence to produce and distribute beloved Australian confectionery brands Violet Crumble, Polly Waffle, and FruChocs across Australia and New Zealand, targeting $6.5 million in net sales.

DGR Global has clarified its board's stance on Jiangxi Copper's takeover offer for SolGold, deeming it significantly undervalued. The company’s final voting position remains undecided ahead of the critical SolGold shareholder meeting.

WIN Metals Ltd has launched a prospectus offering up to 78.57 million free attaching options to recent placement participants and its Executive Chairman, aiming to remove trading restrictions and enable market liquidity. The offer follows a $5.5 million capital raise and comes amid ongoing litigation risks.

Clime Capital Limited signals a strong turnaround with a $7.8 million pretax profit for the half year ending December 2025, reversing last year's loss, and announces a higher franking rate for its upcoming dividend.

Pursuit Minerals Limited has had its trading suspension lifted following the release of its Pre-Feasibility Study and a capital raising announcement, signaling renewed investor interest.

Arena REIT has announced its December 2025 quarter distribution of 4.8125 cents per stapled security, reflecting steady income from its social infrastructure portfolio. The distribution includes components relevant for tax purposes, underscoring the REIT’s ongoing compliance and investor transparency.

Arcadia Minerals has secured a binding term sheet with Hongkong Xinhai Mining Services, granting Xinhai an exclusive option to advance the Swanson Tantalum Project in Namibia towards production through a strategic partnership and investment.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

F.F.I. Holdings anticipates a modest decline in half-year profit, citing one-off lease expenses despite steady food operations.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.